Exelixis (NASDAQ:EXEL) Stock

EXELIXIS INC

Exelixis

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis Inc

EXELA TECHNOLOGIES INC by Exela Technologies, Inc.

Exela Technologies Inc

EXELA TECHS INC 6% SER B by Exela Technologies, Inc.

Exelon Corp

Exelixis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) on Tuesday reported its first quarter of 2025 adjusted earnings of 62 cents per share, compared to 17 cents a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 36 cents</a>.
The cancer-focused company reported quarterly sales of $555.45 million, beating the <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45410642/exelixis-crushes-q1-earnings-estimates-with-strong-cabometyx-sales-raises-2025-revenue-guidance" rel="noreferrer noopener">consensus of $498.18 million</a>.
Total revenues included net product revenues of&nbsp;$513.3 million, compared to&nbsp;$378.5 million&nbsp;for the comparable period in 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44499265/fda-approves-exelixis-lead-cancer-drug-cabometyx-for-expanded-use-in-neuroendocrine-tumors" rel="noreferrer noopener">FDA Approves Exelixis&#8217; Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors</a>
Guidance: &#8220;Based on the strong first quarter dynamics of CABOMETYX, we&#8217;re increasing our 2025 full year financial guidance for net product revenues and total revenues by $100 million,&#8221; <a href="https://www.benzinga.com/general/biotech/25/05/45410642/exelixis-crushes-q1-earnings-estimates-with-strong-cabometyx-sales-raises-2025-revenue-guidance">said</a> Michael M. Morrissey, president and CEO of Exelixis.
The company raised fiscal 2025 sales guidance from $2.15 billion-$2.25 billion to $2.25 billion-$2.35 billion, versus the consensus of $2.25 billion.
Stifel writes, &#8220;We note the NET launch should prove a tailwind to FY25 topline growth and command an additional guidance raise above the $100 million announced today. We continue to believe 2H25 zanzalintinib clinical catalysts will prove a more significant driver of investor enthusiasm&#8230;&#8221;
Analyst Stephen Willey highlights, &#8220;Management noted there is a significant overlap between target NET physicians and legacy Cabometyx prescribers and believes Cabometyx is well positioned to capture a significant portion of the small molecule NET market, which, per management, is estimated at $1B in FY25.&#8221;
Willey maintains the Hold rating for Exelixis and raises the price <a href="https://www.benzinga.com/quote/EXEL/analyst-ratings" target="_blank" rel="noreferrer noopener">target from $36 to $38</a>.
Stifel updated fiscal 2025, 2026 and 2027 Cabometyx sales estimates, primarily reflecting continued first-line RCC share gains and an accelerated NET launch trajectory. The analyst updates sales estimates to $2.141 billion, $2.439 billion and $2.712 billion versus $2.062 billion, $2.35 billion, and $2.54 billion, respectively, expected previously.
EXEL Price Action: Exelixis stock was up 20% at $44.3 at publication on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45411148/taiwan-semiconductor-commits-15-billion-to-chip-expansion-approves-dividend-amid-rising-global-demand" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Commits $15 Billion To Chip Expansion, Approves Dividend</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Earnings

News

Guidance

Health Care

Analyst Ratings

General

EXEL

Exelixis Stock Soars As Analysts Applaud Raised 2025 Guidance, Q1 Earnings Beat

U.S. tech stocks extended their weekly rally into Wednesday's session, lifted by renewed investor appetite for risk following a breakthrough in early-week U.S.-China trade negotiations. This reignited hopes for a more <a href="https://www.benzinga.com/topic/tariffs">stable global trade outlook. </a>
The Nasdaq 100 rose 0.5% by midday in New York, reaching levels last seen in late February. Heavyweight chipmakers led the rally, as Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) surged 4% and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) jumped 5%.
Traders welcomed mounting expectations of large-scale investments from Gulf nations into U.S. tech and semiconductor sectors, as President Donald Trump secured new economic agreements with <a href="https://www.benzinga.com/25/05/45417156/nvidia-amd-stocks-climb-as-trump-plans-to-ease-ai-chip-export-rules">Middle Eastern countries</a>, including Saudi Arabia and Syria.
While the Nasdaq marched higher, the S&amp;P 500 stalled and both the Dow Jones Industrial Average and Russell 2000 slipped slightly, indicating a more selective rally focused on high-growth sectors.
Clean energy and solar stocks outperformed again, building on strong Tuesday gains. Investors cheered a less-severe-than-expected revision to clean energy tax credits in the latest Republican tax proposal.
The commodity space told a different story, with gold prices dropping nearly 2%, breaking below the $3,200 per ounce mark for the first time in over a month. 
The yellow metal is now tracking its worst weekly performance since November 2024, with two trading sessions still left this week.
Investors appear to be rotating out of safe-haven assets, as appetite for equities and riskier plays returns on global trade optimism. 
Rising Treasury yields also weighed on broader market sentiment. The yield on the 2-year Treasury note broke above 4%, hitting its highest level in more than two months. Meanwhile, the 30-year bond yield rose 5 basis points to 4.97%, drawing closer to the psychologically important 5% mark—a level often associated with tightening financial conditions and pressure on long-duration assets.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,273.30</td>
<td>0.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,891.20</td>
<td>0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,075.32</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,089.17</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:15 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) flattened at $586.91.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.3% to $420.45.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.4% to $517.40.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.6% lower to $207.35.</li>
<li>The&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 0.5%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 1.8%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
<ul class="wp-block-list">
<li>Israeli retail broker Etoro Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETOR#NASDAQ">ETOR</a>) made his debut on the Nasdaq 100 index. Shares were up 26%.</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) rallied for a second straight session, jumping 18% to $45.99 on Monday after a 16% gain the previous day.</li>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) advanced 1.9% after securing a major deal with Qatar Airways, which agreed to purchase up to 210 Boeing 787 Dreamliner and 777X aircraft in a transaction valued at $96 billion.</li>
<li>Exelixis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) soared 20% after the biotech firm posted first-quarter earnings and revenue that topped Wall Street estimates.</li>
<li>Stocks slated to report earnings after the close include Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), Copart Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) and Steris plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>). </li>
</ul>
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45414023/magnificent-seven-add-36-trillion-since-april-lows-is-this-rally-just-beginning">Magnificent Seven Add $3.6 Trillion Since April Lows: Is This Rally Just Beginning?</a></li>
</ul>
Image: Shutterstock

Equities

Government

Large Cap

Regulations

Broad U.S. Equity ETFs

Econ #s

Tech

ETFs

CPRT

CSCO

SPDR Dow Jones Industrial Average ETF Trust

ETOR

NVDA

SMCI

Select Sector SPDR-Consumer Discretionary

Tech Stocks Edge Up, AMD Rallies 5%, 30-Year Yields Eye Danger Zone: What's Driving Markets Wednesday?

RBC Capital analyst Gregory Renza reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Outperform and maintains $40 price target.

Price Target

Reiteration

RBC Capital Reiterates Outperform on Exelixis, Maintains $40 Price Target

Exelixis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) reported adjusted earnings of 62 cents per share on Tuesday for the first quarter of 2025, compared to 17 cents a year ago, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 36 cents</a>.
The cancer-focused company reported quarterly sales of $555.45 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45390263/exelixis-announces-first-quarter-2025-financial-results-and-provides-corporate-update" rel="noreferrer noopener">consensus of $498.18 million</a>.
Total revenues included net product revenues of&nbsp;$513.3 million, compared to&nbsp;$378.5 million&nbsp;for the comparable period in 2024.
<ul class="wp-block-list">
<li>The increase in net product revenues was primarily due to an increase in sales volume and an increase in average net selling price.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44499265/fda-approves-exelixis-lead-cancer-drug-cabometyx-for-expanded-use-in-neuroendocrine-tumors" rel="noreferrer noopener">FDA Approves Exelixis&#8217; Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors</a>
&#8220;Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in Cabometyx demand, new patient starts, and revenues,&#8221; said Michael M. Morrissey, president and CEO of Exelixis.
&#8220;The&nbsp;Exelixis&nbsp;commercial team rapidly mobilized for the launch of CABOMETYX in advanced neuroendocrine tumors (NET) within hours of receiving&nbsp;U.S.&nbsp;regulatory approval in late March. We are very pleased with the initial reception and plan to provide further updates to our 2025 financial guidance as we build momentum on the NET launch and gain further clarity on additional revenue opportunities for 2025,&#8221; Morrissey added.
Guidance: &#8220;Based on the strong first quarter dynamics of CABOMETYX, we&#8217;re increasing our 2025 full year financial guidance for net product revenues and total revenues by&nbsp;$100 million,&#8221; Morrissey said.
The company raised fiscal 2025 sales guidance from $2.15 billion—$2.25 billion to $2.25 billion—$2.35 billion, versus the consensus of $2.25 billion.
On Tuesday, Invenra Inc. announced that its collaboration partner, Exelixis, has initiated the dose-escalation stage of the first-in-human Phase 1 study of XB628 in participants with recurrent advanced or <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">metastatic solid tumors</a>.
XB628 is a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45394458/invenra-highlights-exelixis-initiation-of-phase-1-clinical-study-evaluating-xb628-a-first-in-class" rel="noreferrer noopener">death-ligand 1 (PD-L1)</a>.
The molecule was discovered in part through a collaboration between Exelixis and Invenra.
&#8220;Regarding flagship product Cabometyx, we are encouraged by its continued strength in RCC and expect the recent approval in late-line NETs to potentially drive the next leg of growth,&#8221; William Blair analyst Andy T. Hsieh wrote on Wednesday.
&#8220;The NETs market is expected to grow at a 9% compound annual rate to $4.6 billion by 2030. Based on our prior analysis, the total addressable market for Cabometyx in this indication stands at $900 million, thus representing a material expansion opportunity, in our view.&#8221; 
Price Action: At the last check on Wednesday, EXEL stock was up 4.11% at $38.47 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45405716/firstcash-enters-uk-market-with-394-million-acquisition-of-ht-group" target="_blank" rel="noreferrer noopener">FirstCash Enters UK Market With $394 Million Acquisition Of H&amp;T Group</a></li>
</ul>
Photo: Shutterstock

Movers

Trading Ideas

Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance

Morgan Stanley analyst Jefferson Harralson maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Overweight and raises the price target from $40 to $47.

Morgan Stanley Maintains Overweight on Exelixis, Raises Price Target to $47

WIIM

Exelixis shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance with its midpoint above estimates. The company, acting as a collaboration partner of Invenra, initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628.

Invenra's Collaboration Partner Exelixis Initiates The Dose-Escalation Stage Of The First-In-Human Phase 1 Clinical Study Of XB628 In Participants With Recurrent Advanced Or Metastatic Solid Tumors

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) raises FY2025 sales outlook from $2.15 billion-$2.25 billion to $2.25 billion-$2.35 billion vs $2.25 billion estimate.

Exelixis Raises FY2025 Sales Guidance from $2.15B-$2.25B to $2.25B-$2.35B vs $2.25B Est

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.36 by 72.22 percent. This is a 264.71 percent increase over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $555.45 million which beat the analyst consensus estimate of $498.18 million by 11.50 percent. This is a 30.62 percent increase over sales of $425.23 million the same period last year.

Earnings Beats

Exelixis Q1 Adj. EPS $0.62 Beats $0.36 Estimate, Sales $555.45M Beat $498.18M Estimate

ABOS

ABSI

ACCS

ACHV

ACXP

ADAP

ALCO

ALLO

ASNS

AUID

AVXL

BDSX

BEAT

BKTI

BWAY

BWEN

CAMT

CAPR

CINT

CLPT

CLRB

CNCK

CYBR

DARE

DLPN

DMAC

ELMD

ETON

FENC

FLOC

FTHM

GAIN

GAUZ

GENK

GEVO

GNSS

GOCO

GRAL

GUTS

HSON

HUMA

HUYA

HYFM

HYLN

HYPR

ICMB

IMOS

INLX

IRIX

ITRM

IZEA

KOPN

KRMN

LCTX

LEGN

LOAR

LSTR

LUNR

LXRX

MASS

MBRX

MCHX

MDAI

MGNX

MPTI

NMTC

NPCE

NUTX

NUWE

NXGL

NYAX

OKLO

ONON

OPXS

PERI

PRTS

PSFE

PXLW

Earnings Scheduled For May 13, 2025

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Exelixis will report an earnings per share (EPS) of $0.38.
The announcement from Exelixis is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
The company's EPS beat by $0.06 in the last quarter, leading to a 0.03% drop in the share price on the following day.
Here's a look at Exelixis's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.49</td>
<td>0.35</td>
<td>0.30</td>
<td>0.24</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.55</td>
<td>0.47</td>
<td>0.84</td>
<td>0.17</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>13.0%</td>
<td>13.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747072871_0.png" alt="eps graph" />
<h3>Tracking Exelixis's Stock Performance</h3>
Shares of Exelixis were trading at $36.17 as of May 09. Over the last 52-week period, shares are up 77.32%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Exelixis</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Exelixis.
A total of 11 analyst ratings have been received for Exelixis, with the consensus rating being Buy. The average one-year price target stands at $37.82, suggesting a potential 4.56% upside.
<h3>Peer Ratings Overview</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Exact Sciences, Moderna and Biomarin Pharmaceutical, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Exact Sciences, with an average 1-year price target of $63.92, suggesting a potential 76.72% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Moderna, with an average 1-year price target of $42.91, suggesting a potential 18.63% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Biomarin Pharmaceutical, with an average 1-year price target of $94.4, suggesting a potential 160.99% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
In the peer analysis summary, key metrics for Exact Sciences, Moderna and Biomarin Pharmaceutical are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exelixis</td>
<td>Buy</td>
<td>18.16%</td>
<td>$546.79M</td>
<td>6.19%</td>
</tr>
<tr>
<td>Exact Sciences</td>
<td>Outperform</td>
<td>10.86%</td>
<td>$500.55M</td>
<td>-4.22%</td>
</tr>
<tr>
<td>Moderna</td>
<td>Neutral</td>
<td>-35.93%</td>
<td>$17M</td>
<td>-9.26%</td>
</tr>
<tr>
<td>Biomarin Pharmaceutical</td>
<td>Neutral</td>
<td>14.84%</td>
<td>$593.59M</td>
<td>3.24%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Exelixis ranks highest in revenue growth among its peers. It also leads in gross profit margin. However, it has the lowest return on equity.
<h3>Get to Know Exelixis Better</h3>
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>A Deep Dive into Exelixis's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Exelixis's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 18.16%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Exelixis's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 24.68%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Exelixis's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.19% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Exelixis's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.73%, the company showcases efficient use of assets and strong financial health.
Debt Management: Exelixis's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<a href="https://www.benzinga.com/quote/EXEL/earnings">To track all earnings releases for Exelixis visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring Exelixis's Earnings Expectations

Exelixis's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NYSE">EXEL</a>) short percent of float has risen 25.73% since its last report. The company recently reported that it has 18.23 million shares sold short, which is 9.04% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Exelixis Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745931723_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Exelixis has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Exelixis's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Exelixis's peer group average for short interest as a percentage of float is 6.03%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is the Market Bullish or Bearish on Exelixis?

19 analysts have expressed a variety of opinions on Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $37.74, a high estimate of $45.00, and a low estimate of $29.00. Observing a 3.91% increase, the current average has risen from the previous average price target of $36.32. 
<img src="https://www.benzinga.com/files/images/story/2025/1744927228_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Exelixis is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Silvan Tuerkcan &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $41.00&#x7C;$41.00 &#x7C; 
&#x7C;Robert Burns &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;Gregory Renza &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $40.00&#x7C;$38.00 &#x7C; 
&#x7C;Derek Archila &#x7C;Wells Fargo &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $36.00&#x7C;$36.00 &#x7C; 
&#x7C;Peter Lawson &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $29.00&#x7C;$25.00 &#x7C; 
&#x7C;Robert Burns &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;David Lebowitz &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $45.00&#x7C;$38.00 &#x7C; 
&#x7C;Michael Schmidt &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $42.00&#x7C;$42.00 &#x7C; 
&#x7C;Sudan Loganathan &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $29.00&#x7C;$29.00 &#x7C; 
&#x7C;Stephen Willey &#x7C;Stifel &#x7C;Raises &#x7C;Hold &#x7C; $36.00&#x7C;$30.00 &#x7C; 
&#x7C;Joseph Catanzaro &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $38.00&#x7C;$37.00 &#x7C; 
&#x7C;Ashwani Verma &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $34.00&#x7C;$30.00 &#x7C; 
&#x7C;Silvan Tuerkcan &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $41.00&#x7C;$41.00 &#x7C; 
&#x7C;Asthika Goonewardene&#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $43.00&#x7C;$42.00 &#x7C; 
&#x7C;Sudan Loganathan &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $29.00&#x7C;$29.00 &#x7C; 
&#x7C;Robert Burns &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;Jefferson Harralson &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $40.00&#x7C;$30.00 &#x7C; 
&#x7C;Jay Olson &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Perform &#x7C; $33.00&#x7C;$41.00 &#x7C; 
&#x7C;Silvan Tuerkcan &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $41.00&#x7C;$41.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Exelixis. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Exelixis's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Exelixis's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exelixis analyst ratings.</a>
<h2>All You Need to Know About Exelixis</h2>
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Exelixis's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Exelixis showcased positive performance, achieving a revenue growth rate of 18.16% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Exelixis's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 24.68%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Exelixis's ROE stands out, surpassing industry averages. With an impressive ROE of 6.19%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Exelixis's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.73%, the company showcases efficient use of assets and strong financial health.
Debt Management: Exelixis's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Exelixis Through The Eyes Of 19 Analysts

JMP Securities analyst Silvan Tuerkcan reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Market Outperform and maintains $41 price target.

JMP Securities Reiterates Market Outperform on Exelixis, Maintains $41 Price Target

HC Wainwright &amp; Co. analyst Robert Burns reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and maintains $40 price target.

HC Wainwright & Co. Reiterates Buy on Exelixis, Maintains $40 Price Target

The U.S. Food and Drug Administration has approved Exelixis Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) Cabometyx (cabozantinib) for two indications in adult and pediatric patients with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extra-<a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">pancreatic neuroendocrine tumors (NET)</a>.
NETs are heterogeneous tumors arising from the digestive tract&#8217;s neuroendocrine cells and other organs, <a href="https://www.benzinga.com/pressreleases/25/03/b44493504/exelixis-announces-u-s-fda-approval-of-cabometyx-cabozantinib-for-patients-with-previously-treated" target="_blank" rel="noreferrer noopener">such as the lung and pancreas</a>.
The approval comes before the Prescription Drug User Fee Act action&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42896345/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-" rel="noreferrer noopener">date of April 3</a>.
The FDA approval — adding to five previous approvals for Cabometyx — is based on the CABINET Phase 3 trial results.
Final progression-free survival results were&nbsp;<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.exelixis.com%2Fnews-releases%2Fnews-release-details%2Fexelixis-announces-final-results-phase-3-pivotal-cabinet-study&amp;esheet=54210567&amp;newsitemid=20250219147539&amp;lan=en-US&amp;anchor=presented&amp;index=2&amp;md5=7b36ee82c7ce7195ef5a81ef129a2ad8" rel="noreferrer noopener">presented</a>&nbsp;at the 2024 European Society for Medical Oncology Congress and published in&nbsp;The New England Journal of Medicine.&nbsp;
In January 2025, the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Neuroendocrine and Adrenal Tumors were updated to include cabozantinib as a category 1 preferred regimen for the majority of well-differentiated advanced NET following specific treatments and as a category 2A preferred regimen for other forms of advanced NET, depending on tumor grade and different requirements for prior therapy.
In February, Exelixis announced the final results from the phase 3 CheckMate-9ER pivotal trial evaluating Cabometyx (cabozantinib) in combination with Bristol-Myers Squibb Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC).
After more than five years of follow-up, the findings demonstrated that the efficacy benefits of Cabometyx&nbsp;in combination with Opdivo were sustained long-term.
At a median follow-up of 67.6 months, Cabometyx, in combination with Opdivo, improved progression-free survival and overall survival compared with&nbsp;Pfizer Inc&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Sutent (sunitinib) in the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43756537/exelixis-announces-final-five-year-follow-up-results-from-checkmate-9er-trial-evaluating-cabometyx" rel="noreferrer noopener">intent-to-treat population</a>.
EXEL Price Action: EXEL stock is down 2.31% at $36.83 at publication on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44492174/palantir-partners-with-everfox-to-supercharge-us-military-tech" target="_blank" rel="noreferrer noopener">Everfox Partners With Palantir To Supercharge Military Tech: Details</a></li>
</ul>
Photo: Shutterstock

FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors

– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo –
– CABOMETYX is now the first and only systemic treatment that is FDA approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin receptor expression and functional status –
– Exelixis is prepared to immediately support these new indications –
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54210567&amp;newsitemid=20250219147539&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=8dd1e246d676ee983d38fc1b151850a7">Exelixis, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX&#xAE; (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET); and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET). NET are heterogeneous tumors that arise from the neuroendocrine cells of the digestive tract and other organs, such as the lung and pancreas. Most patients with advanced disease face a poor prognosis.1,2,3,4

Exelixis Announces U.S. FDA Approval Of CABOMETYX For Patients With Previously Treated Advanced Neuroendocrine Tumors

Exelixis To Present Preclinical Data For Four Pipeline Molecules At AACR Annual Meeting 2025

Exelixis's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NYSE">EXEL</a>) short percent of float has fallen 17.77% since its last report. The company recently reported that it has 13.29 million shares sold short, which is 6.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.91 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Exelixis Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742931014_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Exelixis has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Exelixis's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Exelixis's peer group average for short interest as a percentage of float is 5.57%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Exelixis's Recent Short Interest

During the last three months, 25 analysts shared their evaluations of Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">8</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $38.32, with a high estimate of $45.00 and a low estimate of $29.00. This current average reflects an increase of 7.88% from the previous average price target of $35.52. 
<img src="https://www.benzinga.com/files/images/story/2025/1741903255_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Exelixis by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$36.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$34.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$43.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jefferson Harralson</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Perform</td>
<td>$33.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$41.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$40.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Exelixis. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Exelixis's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Exelixis's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exelixis analyst ratings.</a>
<h2>About Exelixis</h2>
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Financial Insights: Exelixis</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Exelixis showcased positive performance, achieving a revenue growth rate of 18.16% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Exelixis's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 24.68%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.19%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Exelixis's ROA stands out, surpassing industry averages. With an impressive ROA of 4.73%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Exelixis adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 25 Analyst Ratings Have To Say About Exelixis

Press Releases

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

Small Cap

Opinion

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

Comments

Exelixis

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL